NCT04472910 2026-03-12
NeoPancOne
University Health Network, Toronto
Phase NA Active not recruiting
Clinical Trials
54 trialsNCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT04469556 2026-02-20
PASS-01
University Health Network, Toronto
Phase 2 Completed
NCT06384560 2026-02-13
PREOPANC-5
Amsterdam UMC, location VUmc
Phase 1/2 Recruiting
NCT00208260 2026-02-05
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2/3 Completed
NCT07243288 2025-11-21
RADIOPAN
Assistance Publique - Hôpitaux de Paris
Active not recruiting
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT07208539 2025-10-06
ZSPAC-14
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05132504 2025-07-18
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Phase 2 Recruiting
NCT04594772 2025-07-02
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT04084496 2025-05-30
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05121038 2024-12-17
CENDIFOX
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT06714604 2024-12-03
ADVANTAGE
Sahlgrenska University Hospital
Phase 3 Recruiting
NCT05529940 2024-11-27
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Seoul National University Hospital
Phase 3 Recruiting
NCT04423731 2024-11-20
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
Oslo University Hospital
Active not recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT02352337 2024-07-10
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04589234 2024-04-24
Saltikva for Metastatic Pancreatic Cancer
Salspera LLC
Phase 2 Active not recruiting
NCT01827553 2024-04-11
CONKO-007
University of Erlangen-Nürnberg Medical School
Phase 3 Completed
NCT02128100 2024-03-05
BCC-RAD-13
University of Louisville
Phase 2 Completed
NCT03291899 2024-01-17
FBI-TRAC
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated
NCT05081687 2023-10-11
BRAZIL-TNT
Hospital Israelita Albert Einstein
Phase 3 Unknown
NCT03914170 2023-09-26
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
Completed
NCT04324307 2023-09-01
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Phase 1/2 Unknown
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT04990037 2023-06-29
CAPAFOUR
Cantargia AB
Phase 1 Completed
NCT05868317 2023-05-22
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Phase 2 Unknown
NCT03504423 2023-01-03
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
Phase 3 Completed
NCT02873598 2022-12-19
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
Phase 1 Completed
NCT05181605 2022-08-09
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
Instituto de investigación e innovación biomédica de Cádiz
Phase 2/3 Unknown
NCT05007587 2021-08-16
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Zhejiang Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT01676259 2021-07-02
PROTACT
Silenseed Ltd
Phase 2 Unknown
NCT04270929 2021-06-01
PANC-001
Roger Williams Medical Center
Phase 1 Withdrawn
NCT04897854 2021-05-24
TIMEPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Unknown
NCT03825861 2020-11-10
FOLFIRINOX
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT02717091 2020-09-10
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Nagoya University
Phase 2 Unknown
NCT03600623 2020-08-18
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
University of Alabama at Birmingham
Phase EARLY_PHASE1 Terminated
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02456714 2020-03-10
4CC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT04130399 2019-10-17
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
Phase 2 Withdrawn
NCT03812783 2019-01-23
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT02862015 2017-10-31
Oncothermia
Seoul National University Hospital
Phase 2 Unknown
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01523457 2017-08-30
FOLFIRINOX
Yale University
Phase 2 Completed